Immunwork, Inc., founded in 2014, was a subsidiary of T-E Pharma Holding, focused on the development of innovative platforms and novel drugs. Utilizing the fatty acid bundle platform, we have developed the ultra-long-acting drug candidates for the treatment of critical endocrine diseases, such as diabetes, obesity, acromegaly and neuroendocrine tumors. Two promising candidates are in Phase I clinical trial now.
Another affiliated company, the sister company of Immunwork – T-E Meds, Inc., was established in 2022. It focused on the development of antibody-derived drug candidates by the innovative antibody-drug conjugate (ADC) or antibody-radionuclide conjugate (ARC) platforms. These potential drugs are intended for the treatment of various lethal cancers, including multiple myeloma and pancreatic cancer.
T-E Meds website: https://www.temeds.com/
